How should gestational trophoblastic neoplasia be managed according to the FIGO risk score, including the recommended chemotherapy regimens for low‑risk (score ≤6) and high‑risk (score >6) disease?

Management of Gestational Trophoblastic Neoplasia by FIGO Risk Score

For low-risk GTN (FIGO score ≤6), treat with single-agent methotrexate with folinic acid (MTX/FA) as first-line therapy, continuing for 6 weeks after hCG normalization; for high-risk GTN (FIGO score ≥7), initiate multi-agent EMA/CO chemotherapy, continuing for 6 weeks after hCG normalization (8 weeks if liver or brain metastases present). 1

Low-Risk GTN (FIGO Score 0-6)

First-Line Treatment

The ESMO and RCOG guidelines clearly establish that single-agent chemotherapy is the standard approach for low-risk disease 1, 2. The preferred regimen is:

• Methotrexate 50 mg IM alternating with folinic acid 15 mg PO daily for 1 week, followed by 6 rest days (MTX/FA regimen)
• This is preferred over MTX alone or actinomycin-D because it is less toxic and does not cause alopecia 1
• Alternative: Actinomycin-D 1.25 mg/m² IV every 2 weeks if MTX/FA fails or is contraindicated

Critical treatment duration: Continue chemotherapy until hCG normalizes, then give 6 additional weeks of consolidation therapy 1. This consolidation is mandatory—reducing it by even one cycle doubles relapse risk 1.

Managing Treatment Resistance

Approximately 25% of low-risk patients develop chemoresistance 3. Monitor hCG weekly during treatment to detect resistance early 1. Switch therapy if:

• hCG plateaus or rises on two consecutive measurements
• If hCG <300 IU/L at resistance: Switch to actinomycin-D
• If hCG >300 IU/L at resistance: Switch to multi-agent EMA/CO 1

Important caveat: Patients with FIGO scores of 5-6 have disproportionately high resistance rates (up to 70% fail first-line MTX/FA) 1, 4. Consider starting these patients directly on actinomycin-D or even multi-agent therapy, though guidelines still recommend attempting single-agent first 1.

Outcome

Overall survival approaches 100% even when first-line therapy fails, because salvage regimens are highly effective 1, 5.

High-Risk GTN (FIGO Score ≥7)

First-Line Treatment

EMA/CO is the standard multi-agent regimen for high-risk disease 1, 6:

EMA (Days 1-2):

• Etoposide 100 mg/m² IV
• Methotrexate 300 mg/m² IV infusion over 12 hours
• Actinomycin-D 0.5 mg IV
• Folinic acid 15 mg PO/IM every 12 hours × 4 doses (starting 24 hours after MTX)

CO (Day 8):

• Cyclophosphamide 600 mg/m² IV
• Vincristine 1 mg/m² IV (max 2 mg)

Repeat cycle every 2 weeks.

Treatment duration: Continue until hCG normalizes, then give:

• 6 weeks consolidation for standard high-risk disease
• 8 weeks consolidation if liver or brain metastases present 1

Ultra-High-Risk Disease (FIGO Score ≥13)

For patients with extensive tumor burden, particularly those with liver or brain metastases, start with low-dose induction chemotherapy to prevent early deaths from tumor lysis, hemorrhage, or metabolic complications 1:

• Etoposide 100 mg/m² + cisplatin 20 mg/m² on days 1-2, repeated weekly for 1-3 weeks
• This approach has virtually eliminated early deaths and improved overall survival to >94% 1
• After induction, transition to standard EMA/CO or consider EMA/EP for ultra-high-risk features

Brain Metastases

Requires modified approach:

• Intrathecal methotrexate may be added
• Consider neurosurgical intervention if indicated
• Extend consolidation to 8 weeks 1, 7

Managing Treatment Resistance

Approximately 20% of high-risk patients progress on or relapse after primary chemotherapy, but 75-80% are still salvaged 1. Salvage options include:

1. EP/EMA regimen: Etoposide/cisplatin alternating with EMA (survival >80% but significant toxicity) 1
2. TP/TE regimen: Paclitaxel/cisplatin alternating with paclitaxel/etoposide (better tolerated than EP/EMA) 1
3. Surgical resection of isolated resistant foci (can be curative if hCG falls appropriately post-op) 1

Outcome

Survival rates are approximately 90-94% for high-risk disease with modern multi-agent chemotherapy 1, 7, 5.

Critical Management Principles

hCG Monitoring

• Measure weekly during treatment to detect resistance early 1
• After achieving remission, continue monitoring for 6 months (complete mole) or until two normal values 4 weeks apart (partial mole) 2

Residual Masses

Do not surgically remove residual lung or uterine masses after chemotherapy—they do not predict recurrence (risk <3%) and surgery is unnecessary 1

Common Pitfall

The FIGO scoring system has a critical weakness: patients with scores of 5-6 behave more like high-risk disease in terms of chemoresistance, yet are classified as low-risk 1, 4. Be prepared for treatment failure in this subgroup and maintain a low threshold for escalating therapy.